Publication


Featured researches published by S. Paul Lee.


Assay and Drug Development Technologies | 2010

Triphenylphosphine Oxide Is a Potent and Selective Inhibitor of the Transient Receptor Potential Melastatin-5 Ion Channel

R. Kyle Palmer; Karnail S. Atwal; Ivona Bakaj; Stacy Carlucci-Derbyshire; M. N. Tulu Buber; Rok Cerne; Rosa Y. Cortés; Heather Devantier; Vincent Jorgensen; Aaron Pawlyk; S. Paul Lee; Dennis Sprous; Zheng Zhang; Robert W. Bryant

Transient receptor potential melastatin-5 (TRPM5) is a calcium-gated monovalent cation channel expressed in highly specialized cells of the taste bud and gastrointestinal tract, as well as in pancreatic β-cells. Well established as a critical signaling protein for G protein-coupled receptor-mediated taste pathways, TRPM5 also has recently been implicated as a regulator of incretin and insulin secretion. To date, no inhibitors of practical use have been described that could facilitate investigation of TRPM5 functions in taste or secretion of metabolic hormones. Using recombinant TRPM5-expressing cells in a fluorescence imaging plate reader-based membrane potential assay, we identified triphenylphosphine oxide (TPPO) as a selective and potent inhibitor of TRPM5. TPPO inhibited both human (IC₅₀ = 12 μM) and murine TRPM5 (IC₅₀ = 30 μM) heterologously expressed in HEK293 cells, but had no effect (up to 100 μM) on the membrane potential responses of TRPA1, TRPV1, or TRPM4b. TPPO also inhibited a calcium-gated TRPM5-dependent conductance in taste cells isolated from the tongues of transgenic TRPM5(+/)⁻ mice. In contrast, TPP had no effect on TRPM5 responses, indicating a strict requirement of the oxygen atom for activity. Sixteen additional TPPO derivatives also inhibited TRPM5 but none more potently than TPPO. Structure-activity relationship of tested compounds was used for molecular modeling-based analysis to clarify the positive and negative structural contributions to the potency of TPPO and its derivatives. TPPO is the most potent TRPM5 inhibitor described to date and is the first demonstrated to exhibit selectivity over other channels.


Archive | 2006

High throughput screening assay for the trpm5 ion channel

Robert W. Bryant; S. Paul Lee; R. Kyle Palmer; Qifeng Yang; M. N. Tulu Buber


Archive | 2008

Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release

S. Paul Lee; Peihong Zhou; M. N. Tulu Buber; Rok Cerne; Robert G. Bryant; F. Raymond Salemme; Gillian Morgan


Archive | 2007

TRPV1 ANTAGONISTS AND USES THEREOF

R. Kyle Palmer; Daniel Long; Heather Devantier; S. Paul Lee; M. N. Tulu Buber; Robert G. Bryant


Archive | 2008

Modulation of the cooperativity between the ion channels trpm5 and trpa1

S. Paul Lee; Tulu Buber; Rok Cerne; Robert W. Bryant


The FASEB Journal | 2007

Thymol and related phenols are potent activators of the transient receptor potential channel, TRPA1

S. Paul Lee; M. N. Tulu Buber; Rok Cerne; Rosa Y. Cortés; Robert W. Bryant


Archive | 2008

Modulation de la capacité de coopération entre les canaux ioniques trpm5 et trpa1

S. Paul Lee; Tulu Buber; Rok Cerne; Robert W. Bryant


Archive | 2008

Non-desensitizing mutant of the transient receptor potential TRPM5 ion channel

Robert W. Bryant; S. Paul Lee; Rok Cerne; M. N. Tulu Buber; Ivona Bakaj; Roy Kyle Palmer


Archive | 2008

Verwendung eines trpm5-hemmers zur regulierung von insulin- und glp-1-freisetzung

S. Paul Lee; Peihong Zhou; M. N. Tulu Buber; Rok Cerne; Robert G. Bryant; F. Raymond Salemme; Gillian Morgan


Archive | 2008

Utilisation d'un inhibiteur de trpm5 pour réguler une sécrétion d'insuline et de glp-1

S. Paul Lee; Peihong Zhou; M. N. Tulu Buber; Rok Cerne; Robert G. Bryant; F. Raymond Salemme; Gillian Morgan

Researchain Logo
Decentralizing Knowledge